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Abstract
Elevated epidermal growth factor receptor (EGFR) and
mammalian target of rapamycin (mTOR) signaling are
known to contribute to the malignant properties of
glioblastoma multiforme (GBM), which include un-
controlled cell proliferation and evasion of apoptosis.
Small molecule inhibitors that target these protein
kinases have been evaluated in multiple clinical trials
for cancer patients, including those with GBM. Here we
have examined the cellular and molecular effects of a
combined kinase inhibition of mTOR (rapamycin) and
EGFR (EKI-785) in U87 and U251 GBM cells. Simulta-
neous treatment with rapamycin and EKI-785 results in
synergistic antiproliferative as well as proapoptotic
effects. At a molecular level, rapamycin alone signifi-
cantly decreases S6 phosphorylation, whereas EKI-785
alone promotes substantially reduced signal trans-
ducer and activator of transcription (STAT3) phosphory-
lation. Treatment with rapamycin alone also increases
Akt phosphorylation on Ser-473, but this effect is
blocked by a simultaneous administration of EKI-785.
Individually, EKI-785 diminishes while rapamycin pro-
motes the binding of the translation inhibitor eukaryotic
initiation factor 4E binding protein (4EBP1) to the eu-
karyotic translation initiation factor 4E (eIF4E). In spite
of these opposing effects, the highest level of 4EBP1–
eIF4E binding occurs with the combination of the two
inhibitors. These results indicate that the inhibition of
EGFR and mTOR has distinct as well as common sig-
naling consequences and provides a molecular ratio-
nale for the synergistic antitumor effects of EKI-785 and
rapamycin administration.
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Introduction
Constitutive activation of mitogenic signaling pathways is a
hallmark of cancer, and a variety of small molecule inhibitors
that block the activities of key signaling mediators in these
pathways are being developed and used in cancer therapy.
The results of clinical studies conducted to date suggest, how-
ever, that single-agent therapies have a limited efficacy against
most solid tumors. These observations have prompted a grow-
ing appreciation for potential benefits in a subset of patients
using combination therapies, in which multiple signaling medi-
ators are simultaneously targeted. Given the large number of
inhibitors currently in development, the preclinical testing and
identification of agents showing additive or synergistic anti-
tumor effects have become an area of intense research.
A pair of key signaling mediators, whose constitutive kinase
activities have been associated with the malignant phenotype
of many cancers, are epidermal growth factor receptor (EGFR)
and mammalian target of rapamycin (mTOR) [1–4]. Early
clinical trials have demonstrated the antitumor effects of EGFR
or mTOR inhibitor–based therapies for subsets of cancer pa-
tients [5,6], and these results have prompted significant interest
in testing inhibitors of these signaling mediators in combination.
The importance of EGFR constitutive activation has been
well-established especially in glioblastoma multiforme (GBM),
an aggressive primary brain tumor in which the gene for
EGFR is frequently amplified and/or mutated [7,8]. EGFR
signals through multiple downstream effectors, including
signal transducer and activator of transcription 3 (STAT3) and
phosphatidylinositol-3 kinase (PI3K), and the increased activi-
ties of these signaling mediators have been linked with tumor
cell proliferation, invasion, evasion of apoptosis, and tumor
angiogenesis [9–11]. In many tumor types, including GBM, in-
activating mutations of the PTEN tumor suppressor also con-
tribute to an increased PI3K signaling activity and a consequent
downstream activation of Akt and mTOR signaling. mTOR
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regulates the translation of a subset of mRNA, many of which
encode for proteins involved in driving cell growth, prolifera-
tion, and angiogenesis [6]. mTOR inhibitors have shown
promising results in several tumor types, including GBM.
Moreover, the observation that loss of PTEN function confers
an increased sensitivity to mTOR inhibitors has further stim-
ulated interest in the clinical use of these agents [12–15].
Here we evaluate the cellular and molecular effects of
singular and combined mTOR and/or EGFR inhibition in two
commonly investigated GBM cell lines. The treatment of
U87 and U251 cells with rapamycin (an mTOR inhibitor)
and EKI-785 (an EGFR inhibitor) [16,17] results in synergistic
antiproliferative and proapoptotic effects, and a molecular
analysis of multiple downstream signaling mediators shows
that these biologic effects are due to distinct as well as con-
vergent agent activities.
Materials and Methods
Drugs and Cell Lines
Rapamycin was obtained from the Developmental Thera-
peutics Program at the National Cancer Institute (Frederick,
MD) (http://dtp.nci.nih.gov/docs/misc/available_samples/
dtp_indsamples.html). A stock solution of 100 mM was pre-
pared in 95% ethanol and stored at 20jC. EKI-785 was
kindly provided by Wyeth-Ayerst (Madison, NJ) (courtesy of
Dr. Lee Greenberger). A stock solution of 10 mM was pre-
pared in dimethyl sulfoxide and stored at 20jC. The U87
and U251 glioma cell lines (American Type Culture Collec-
tion, Manassas, VA) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum. Cells
were maintained under subconfluent conditions at 37jC in
an atmosphere of humidified 5% (vol/vol) CO2. Where indi-
cated, the serum-containing medium was replaced with a
serum-free medium supplemented with 10 ng/ml epidermal
growth factor (EGF) (Cell Signaling, Beverly, MA). Most anti-
bodies used in this study were purchased from Cell Signal-
ing: eukaryotic initiation factor 4E binding protein (4EBP1;
cat. no. 9452), ribosomal S6 (cat. no. 2212), phospho-S235/
236 S6 (cat. no. 2211), STAT3 (cat. no. 9132), phospho-
Y705 STAT3 (cat. no. 9131), phospho-Y1068 EGFR (cat. no.
2236), Akt (cat. no. 9272), phospho-S473 Akt (cat. no. 9271),
and eukaryotic translation initiation factor 4E (eIF4E; cat. no.
9742). TheEGFR antibody used for immunoprecipitation was
purchased from Upstate Biotechnology (Lake Placid, NY; cat.
no. 05-483), and the EGFR antibody used for immunoblotting
was from Cell Signaling (cat. no. 2232). An antibody that spe-
cifically recognized cleaved p85 PARP was from Promega
(Madison, WI; cat. no. G7341). 7-Methyl-GTP Sepharose
beads were from Amersham Biosciences (Piscataway, NJ;
cat. no. 27-5025-01).
MTS Assay
Cell growth was measured using the nonradioactive
MTS assay according to the manufacturer’s instructions
(Promega). Briefly, cells were plated in 96-well plates at a
density of 1000 cells/well. Four wells were plated for each
drug treatment condition. After overnight incubation, the
medium was replaced with a drug-containing medium, and
cells were incubated for an additional 72 hours. Cells were
treated with serial dilutions of each drug individually and with
both drugs simultaneously at a fixed ratio. The MTS reagent
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] and an electron transfer–
coupling reagent (phenazine methosulfate) were added to
the culture medium and incubated for 2 hours. The conver-
sion of the MTS salt to a soluble formazan product was
measured by spectrophotometry. The effects of various con-
centrations of the drugs were compared to untreated samples.
14C–3H Thymidine Incorporation Assay
Cells were plated in 96-well plates (1000 cells/well)
and incubated for 48 hours with 14C thymidine (1 nCi/well,
59 mCi/mmol). Six wells were plated for each drug treatment
condition. Rapamycin and/or EKI-785 then was added at
the indicated concentrations and incubated for an additional
24 hours. Cells were pulsed with 3H thymidine (1.25 mCi/well,
20 Ci/mmol; Perkin-Elmer, Foster City, CA) for 2 hours. Cells
were harvested by trypsinization, transferred onto glass
filters, and lysed in distilled water. Dual-parameter scintilla-
tion counting was used to detect radioactive decay from filter-
bound 3H and 14C.
Apoptosis
The DNA-specific fluorochrome Hoechst 33342 was used
to analyze the nuclear morphology of the cells following drug
treatment. Exponentially growing cells were treated with the
indicated drug concentrations and incubated for 24 hours,
and then floating and adherent cells were harvested and fixed
in methanol/glacial acetic acid (3:1 vol/vol) overnight. Fixed
cells were cytospun onto slides and stained with 1 mg/ml
Hoechst dissolved in a glycerol/0.1 M Tris (pH 7.0) solution
(1:1 vol/vol), and then apoptotic nuclei were counted under
a fluorescent microscope [18].
Immunoblotting
Cells were plated overnight and then incubated with the
indicated drugs for 24 hours in DMEM supplemented with
either 10 ng/ml EGF or 10% fetal calf serum (FCS). Cells were
washed in PBS and then lysed in buffer A (20 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM sodium fluoride,
1% NP-40, 0.5% sodium deoxycholate, 10 mM b-glycerol
phosphate, 10 mg/ml aprotinin, 10 mg/ml pepstatin, 10 mg/ml
leupeptin, 20 nM microcystin, 1 mM PMSF, 1 mM sodium
orthovanadate, 20 nM microcystin, and 10 nM okadaic acid).
Lysates were cleared of insoluble materials by centrifuga-
tion. Samples were boiled in sodium dodecyl sulfate (SDS)
sample buffer, equal amounts of protein were loaded and
run on SDS polyacrylamide gel electrophoresis (PAGE) gels,
and resolved proteins were transferred to Immobilon-P mem-
branes (Millipore, Billerico, MA). Membranes were blocked
with 5% milk dissolved in Tris-buffered saline containing
0.02% Tween 20 and then incubated with a primary anti-
body diluted in the same buffer. After washing, membranes
were incubated with either goat antirabbit (Cell Signaling) or
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goat antimouse (Pierce, Rockford, IL) antibodies conjugated
to horseradish peroxidase. Blots were developed with the
Super Signal Chemiluminescence reagent (Pierce). Typically,
immunoblotting was first performed with phosphospecific anti-
bodies and then membranes were stripped and reprobed with
relevant nonphosphospecific antibodies.
Immunoprecipitation
Cells were handled as described for immunoblotting and
then lysed in buffer B (20 mM HEPES, pH 7.5, 150 mM
NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 1% Triton
X-100, 10 mg/ml aprotinin, 10 mg/ml pepstatin, 10 mg/ml leu-
peptin, 20 nM microcystin, 100 mM PMSF, and 1 mM sodium
orthovanadate). Lysates were cleared of insoluble materials
by centrifugation, and equal amounts of detergent-soluble
proteins were incubated on ice for 30 minutes with appro-
priate primary antibodies. The immune complexes then were
precipitated with protein A Sepharose beads, and the result-
ing immunoprecipitates were washed twice in lysis buffer.
Samples were boiled in an SDS sample buffer, eluted off the
beads, and then processed as above for immunoblotting.
eIF4E/4EBP1 Pull-Down Assay
The 4EBP1 pull-down assay was performed essentially
as described by Dilling et al. [19]. Cells were handled and
lysed in buffer A as described above for immunoblotting.
After clearing by centrifugation, lysates were rotated with
7-methyl-GTP Sepharose beads overnight at 4jC. Beads
were washed thrice in lysis buffer and boiled in SDS sample
buffer prior to the elution of proteins off the beads. The
samples were separated by SDS-PAGE and processed for
immunoblotting as described above.
Statistical Testing
Analysis of synergy was performed with the median ef-
fect method, as described by Chou and Talalay [20], using
the CalcuSyn software program (Version 1.1; BioSoft, Inc.,
Ferguson, MO; http://www.biosoft.com). This method al-
lows for the calculation of a combination index (CI), where a
CI value < 1 indicates a synergistic interaction between two
drugs. The effects of drug treatment on apoptosis and pro-
liferation were analyzed using a two-tailed Student’s t test.
MTS data for EKI-785 treatment were fitted with a three-
parameter Hill equation to determine the IC50 using the
SigmaPlot analysis package.
Results
Glioma Cell Growth Inhibition
The effects of rapamycin and/or EKI-785 on cell prolifer-
ationwere initially assessedusing theMTSassay (Figure1A).
The results of this analysis indicated U87 cells as being
similarly sensitive to all concentrations of rapamycin that
were tested, whereas the growth of U251 cells was little
affected by rapamycin concentrations as high as 100 nM.
Serum concentrations of 10 nM rapamycin or greater are
readily achieved in patients. Treatments with EKI-785
revealed a distinct ordering of cell line sensitivities, with the
IC50 of U87 being almost two-fold higher than that of U251
(4.8 vs 2.8 mM, respectively). Cells were also exposed to mul-
tiple drug concentration combinations, with the rapamycin/
EKI-785 concentrations ratio being fixed at 1:100. For
each cell line, the effect of the combination exceeded that
of either agent used singularly (Figure 1A). To assess poten-
tial synergistic interactions between these drugs, MTS data
were analyzed using the median effect method of Chou
and Talalay [20]. Data analysis through this method gener-
ates a CI for each drug concentration combination, with a CI
value less than 1 indicating a synergistic interaction between
two drugs. As shown in Figure 1B, synergy was evident at
nearly all drug concentration combinations tested for each
cell line.
Assessment of Cell Proliferation and Apoptotic Effects
Because the antigrowth effects of combined-agent treat-
ments could result from decreased cell proliferation and/or
increased cell death, we examined the effects of drug
treatment on DNA synthesis and apoptosis induction sepa-
rately. To quantitate antiproliferative effects, cells were pre-
labeled with 14C thymidine (48 hours); incubated with varying
concentrations of rapamycin, EKI-785, or both drugs for
24 hours; and then pulsed with 3H thymidine (2 hours).
3H/14C ratios were calculated as a measure of the proportion
of cells traversing S-phase. As seen in Figure 2A, the com-
bination of rapamycin and EKI-785 suppressed proliferation
significantly more than rapamycin alone at multiple drug con-
centration combinations in U87 cells but only at high concen-
trations in U251 cells (P < .05).
Apoptosis induction was evaluated by staining nuclear
DNA with Hoechst 33342 and counting the fraction of cells
with condensed chromatin [18]. Incubation with 100 nM rapa-
mycin for 72 hours had relatively little effect on apoptosis
induction in U87 cells (Figure 2, B and C), whereas the dif-
ference between treated and untreated U251 cells (1% and
5%, respectively) was statistically significant. Higher and
statistically significant levels of apoptosis were induced in
U87 and U251 cells by incubation with either 10 mM EKI-785
alone [9% for U87 (P = .03); 23% for U251 (P = .05)] or with
10 mM EKI-785 combined with 100 nM rapamycin [18% for
U87 (P = .02) and 30% for U251 (P = .02)]. Western blot
analysis demonstrating increased levels of cleaved PARP
following treatment with EKI-785, alone or in combination
with rapamycin (Figure 2D), provided biochemical confirma-
tion for the induction of apoptosis in both cell lines.
Inhibition of mTOR Signaling
To elucidate the molecular basis of single and combined
inhibitor treatments on cell proliferation and apoptotic re-
sponse, we examined the effects of EKI-785 and/or rapa-
mycin treatment on the phosphorylation state of signaling
mediators downstream of EGFR and/or mTOR. Two key tar-
gets of mTOR are p70S6 kinase (p70S6K) and 4EBP1, each
of which has activities that promote the translation of mRNA,
whose corresponding proteins drive cell proliferation [21].
As expected, incubation of cells with rapamycin completely
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blocked the mTOR/p70S6K–dependent phosphorylation
of ribosomal S6 without altering the cellular levels of total
S6, whereas EKI-785 had no effect on S6 phosphorylation
(Figure 3A). Similarly, EKI-785 had no observable influence
on 4EBP1 phosphorylation, as indicated by the lack of effect
on the electrophoretic mobility of 4EBP1. Rapamycin re-
duced 4EBP1 phosphorylation, and the extent of this effect
was consistent with the observation that mTOR phosphor-
ylates only a subset of 4EBP1 phosphorylation sites [22].
Importantly, the combined treatment with rapamycin and
EKI-785 was markedly more effective in suppressing
4EBP1 phosphorylation compared to either drug alone
(Figure 3A), and this effect was similar to that resulting from
the treatment of cells with the PI3K inhibitor LY294002.
Figure 1. Growth inhibition of glioma cells by rapamycin and EKI-785. U87 and U251 cells were incubated for 72 hours with the indicated concentrations of
rapamycin and EKI-785, both individually and in 1:100 molar ratio combinations. The effects on cell number were assessed using an MTS colorimetric cell growth
assay. (A) Changes in absorbance, relative to a value of 1 for untreated controls, are shown for the indicated drug concentrations and combinations. Results have
been plotted as mean ± SEM for three independent experiments. *P < .05 and #P = .06, as indicated by Student’s t test results, for rapamycin versus EKI-785 +
rapamycin. yP < .05, for EKI-785 vs EKI-785 + rapamycin. (B) The MTS data from (A) were analyzed for synergy using the median effect method, and the CI values
were plotted relative to corresponding fractional affects. Each point on the graph is labeled with a letter that corresponds to a rapamycin/EKI-785 combination noted
with the same letter in panel A. CI values less than 1 reflect a synergistic interaction between the drugs.
Figure 2. Effects on proliferation and apoptosis with drug treatment. (A) U87 and U251 cells were preincubated with 14C thymidine for 48 hours and then incubated
with the indicated drug concentrations, singularly or in combination, for an additional 24 hours. Cells were then pulsed with 3H thymidine for 2 hours. For each sample,
the DNA was precipitated on glass filters, and filter-bound 3H and 14C radioactivities were measured by scintillation counting. Results shown are normalized relative
to 1 for untreated controls and represent the mean ± SEM of three independent experiments. *P < .05, as indicated by Student’s t test results for rapamycin versus
EKI-785 + rapamycin. yP < .05, for EKI-785 vs EKI-785 + rapamycin. (B) U87 and U251 glioma cells were incubated with rapamycin and/or EKI-785 for 72 hours. Cells
then were fixed and their nuclei were stained with Hoechst 33342. Representative photomicrographs of U87 cells treated with 100 nM rapamycin and/or 10 M
EKI-785 are shown. Nuclei with apoptotic morphology are indicatedwith an asterisk (*). (C) The fraction of cells with apoptoticmorphologywas quantitated. The values
graphed represent the mean ± SEM of three independent experiments, with 500 cells examined per cell line per experiment. *P < .05, as indicated by Student’s t test
for rapamycin versus EKI-785 + rapamycin. yP < .05, for EKI-785 vs EKI-785 + rapamycin. (D) Western blot analysis for the extent of PARP cleavage in association
with single- and combined-agent treatments of U87 and U251 cells for 48 hours. Results show that both EKI alone (10 M) and EKI in combination with rapamycin
(100 nM) induce a substantial PARP cleavage.
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4EBP1 binds to and inhibits the activity of eIF4E, which is
constitutively bound to the 7-methyl-GTP cap structure of
cytoplasmic mRNA [23]. Because phosphorylation of 4EBP1
disrupts its inhibitory binding of eIF4E, we investigated
the effects of small molecule inhibitors on this interaction.
Following the treatment of cells with EKI-785 and/or rapa-
mycin, cellular eIF4E was pulled down by incubating cell ly-
sates with 7-methyl-GTP Sepharose beads. In exponentially
growing, control-treated cells, only a small amount of 4EBP1
coprecipitated with eIF4E (Figure 3B), whereas rapamycin
treatment resulted in an increased 4EBP1–eIF4E asso-
ciation, as was to be expected based on the 4EBP1 phos-
phorylation analysis. Surprisingly, the treatment of cells with
EKI-785 alone reduced the association of 4EBP1 with eIF4E
relative to control; in combination with rapamycin, however,
this EKI-785–associated effect was not evident. Moreover, in
U87 cells, which were the most sensitive to combination
therapy (see Figure 1A), treatment with both rapamycin and
EKI-785 resulted in an enhanced association of 4EBP1 with
eIF4E compared to rapamycin alone.
Inhibition of EGFR Signaling
Incubation of either glioma cell line with EKI-785, alone or
in combination with rapamycin, led to a significant attenua-
tion of EGFR Tyr-1068 autophosphorylation in conjunction
with a significant accumulation of EGFR with a reduced
Figure 3. Immunoblot analysis of mTOR and EGFR signaling mediators. U87 and U251 cells cultured in medium with 10% FCS were incubated for 24 hours with
10 nM rapamycin and/or 10 M EKI-785, or with 40 M LY294002. Cells were lysed, and whole cell lysates were processed for immunoprecipitation and/or
immunoblotting, as indicated. (A) The phosphorylation of mTOR signaling mediators ribosomal S6 protein and 4EBP1 was assessed in whole cell lysates. For
4EBP1, three distinct bands (a, , and c) are readily detectable by SDS-PAGE, and shifts from the highest (a) to the lowest mobility (c) reflect an increasing 4EBP1
phosphorylation on multiple serine/threonine residues. Results shown are representative of four independent experiments. (B) Cells were treated as described
above, and whole cell lysates were incubated with 7-methyl-GTP Sepharose beads. Proteins were eluted off the beads and processed for immunoblotting with
antibodies directed against 4EBP1 and eIF4E. Results shown are representative of three independent experiments for U87 cells and two independent experiments
with U251 cells. (C) EGFR and STAT3 were immunoprecipitated from whole cell lysates, and phosphorylation status was assessed by immunoblotting. Low
(bracket) and high (arrow) electrophoretic mobility forms of EGFR are seen, with increased low-mobility EGFR being readily evident in cells treated with EKI-785,
alone or in combination with rapamycin. (D) Akt phosphorylation was assessed by an immunoblotting of total proteins from whole cell lysates. (E) Cells were
cultured in a serum-free medium supplemented with EGF and indicated drugs for 24 hours and then processed for phospho-Akt immunoblotting. Each of the results
shown in (C), (D), or (E) is representative of two or more independent experiments.
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electrophoretic mobility (Figure 3C). Rapamycin treatment
alone had no significant effect on EGFR phosphorylation
status or expression. EGFR Tyr-1068 autophosphorylation
is required for the receptor-mediated activation and phos-
phorylation of the STAT3 transcription factor [9,24], and, not
surprisingly, EKI-785 effectively blocked STAT3 phosphory-
lation. As with EGFR autophosphorylation, rapamycin treat-
ment had no effect on cellular levels of phospho-STAT3.
Akt is an important signaling mediator that is influenced
by multiple factors, and we hypothesize that Akt inhibition, in
association with EKI-785 and rapamycin treatments, might
contribute to the antiproliferative and proapoptotic effects
of combined-agent administrations. As reported previously,
rapamycin treatment alone resulted in a modest increase in
Akt phosphorylation. Interestingly, although EKI-785 alone
did not alter Akt phosphorylation, it effectively blocked the
rapamycin-associated increase in phospho-Akt (Figure 3D).
Both U87 and U251 cells lack wild-type PTEN function,
which normally dampens the PI3K-dependent activation of
Akt. ecause multiple receptor tyrosine kinases, in addition to
EGFR, modulate the PI3K/Akt signaling pathway, we rea-
soned that compensatory RTK activities that are stimulated
by growth factors present in FCS might contribute to the
failure of EKI-785 to block Akt phosphorylation. To test this
possibility, we repeated our experiments in cells cultured
in serum-free medium supplemented with EGF only. Under
these conditions, EKI-785 effectively reduced Akt phos-
phorylation (Figure 3E ). Similar compensatory signaling path-
ways likely contribute to the resistance of S6 and 4EBP1
phosphorylations to EKI-785 treatment in serum-containing
medium (Figure 3A).
Discussion
Novel treatment regimens using combinations of molecularly
targeted therapeutics are being developed and tested in
cancer therapy.Our data suggest that combining anEGFR in-
hibitor with an mTOR inhibitor results in a synergistic growth
inhibition of glioma cells in vitro compared to treatments with
either inhibitor alone, and that both antiproliferative and pro-
apoptotic effects contribute to this synergistic activity. Fur-
thermore, this effect is associated with the inhibition of
multiple downstream signaling mediators, as revealed by
phosphoprotein immunoblot analysis (Figure 3). Of the sig-
naling mediators we have examined, STAT3 and EGFR were
substantially inhibited by EKI-785, whereas rapamycin sig-
nificantly blocked p70S6 kinase activity. These observations
correspond well with results recently reported in a similar
study where the GBM cell line D54MG was tested for re-
sponses to a different mTOR inhibitor (RAD001), and a multi-
targeted kinase inhibitor (AEE788 inhibits EGFR, HER2 and
VEGFR) with each agent tested singularly as well as
in combination [25].
The current study extends previous observations to
identify potential points of convergence between the EGFR
and mTOR signaling pathways that may contribute to the
antitumor effects of combined small molecule inhibitor ad-
ministrations (Figure 4). Although the suppression of Akt
phosphorylation with rapamycin treatment in HEK293 cells
has been reported [26], our results (Figure 3D) are consis-
tent with other reports demonstrating an upregulation of
Akt activity in 3T3-L1 adipocytes or Kc167 Drosophila
cells treated with rapamycin, in Drosophila larvae express-
ing mutant dTOR, and in HEK293 cells overexpressing
kinase-dead mTOR or dominant-negative p70S6K con-
structs [27–29]. mTOR forms distinct complexes with the
associated raptor or rictor proteins, and a recent study
demonstrated that the mTOR/rictor complex directly phos-
phorylates Akt on Ser-473 and that this activity is insensitive
to rapamycin [30]. Collectively, these studies suggest that
the inhibition of the raptor/mTOR complex by rapamycin, in
some model systems, results in an upregulation of mTOR/
rictor activity and a resulting increased phosphorylation of
Akt. Our observation, that EKI-785–mediated inhibition of
EGFR activity blocks this rapamycin-induced upregulation
of Akt phosphorylation, suggests that EGFR signaling in some
waymodulates this feedback loop. Because Akt signaling pro-
motes cell proliferation and evasion of apoptosis, the inhibi-
tion of rapamycin-induced Akt phosphorylation by EKI-785
could well contribute to the antiproliferative and proapoptotic
effects of these two drugs when used in combination.
An additional single-agent effect of significance is the in-
crease in EGFR that results from the treatment of cells with
EKI-785 (Figure 3C). Our EGFR Western blot analyses
show both low- and high-mobility forms of the receptor, as
reported by others who have established that the low-mobility
form is preferentially localized to the cell membrane [31].
Although not specifically examined here for cellular localiza-
tion, an increase in low-mobility EGFR isoform following EKI-
785 treatment suggests that this inhibitor causes an
accumulation of fully processed EGFR at the plasma mem-
brane, consistent with a cellular homeostatic response to
loss of EGFR signaling. This membrane accumulation may
sensitize tumor cells to treatment with EGFR-targeted
Figure 4. Schematic of EGFR and mTOR signaling network, and signaling
mediator effects associated with rapamycin and/or EKI-785 treatments. A
notation of an ‘‘E’’ or ‘‘R,’’ in association with a signaling pathway, indicates
where the pathway is blocked by EKI-785 or rapamycin, respectively.
Signaling Disruption with mTOR/EGFR Inhibition Rao et al. 927
Neoplasia . Vol. 7, No. 10, 2005
antibodies, as has recently been demonstrated using the
combination of small molecule kinase inhibitors and EGFR-
targeted antibodies in various tumor models [32,33].
For the combination therapy investigated in the present
study, our results suggest that EGFR- and mTOR-dependent
signaling converge on the translational repressor 4EBP1. The
mTOR-dependent phosphorylation of 4EBP1 on Thr-37 and
Thr-46 serves as a priming event that allows a further
phosphorylation of Thr-70, Ser-65, and possibly other sites
by additional signaling mediators [22,34,35]. The phosphory-
lation of 4EBP1 on these residues disrupts the inhibitory
binding of 4EBP1 to eIF4E and thereby promotes an in-
creased protein translation efficiency for mRNA transcripts
with complex 5V untranslated regions (UTRs) [23]. EKI-785
treatment alone actually decreases the inhibitory inter-
action of 4EBP1 with eIF4E (Figure 3B), which suggests that
single-agent EGFR inhibitor therapy may actually promote
the translation of complex 5V UTR–containing transcripts,
some of which encode for proteins involved in driving cell
proliferation and angiogenesis. In contrast, the combination
of EKI-785 with rapamycin treatment promoted the maximal
binding of 4EBP1 to eIF4E. The suppression of eIF4E ac-
tivity by 4EBP1 binding is critically important for the anti-
tumor effects of rapamycin [19]. Thus, the converging effects
of mTOR and EGFR inhibition on increasing 4EBP1/eIF4E
binding are likely to be important contributors to the syner-
gistic growth-suppressive effects of combinedEGFR–mTOR
inhibitor therapy.
In total, our results suggest that compensatory signaling
mechanisms may limit the efficacy of single-agent therapies,
and that the simultaneous inhibition of multiple enzyme
activities reduces the effects of such feedback compensa-
tions. Moreover, the suppression of multiple kinase activities
provides additive inhibitory effects by acting on parallel and
convergent signaling pathways. These molecular observa-
tions, combined with associated biologic responses, provide
a basis for some optimism on improved outcomes for GBM
patients treated with novel combination therapy regimens.
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